GlassScriptPhysician profile
James A Till
NPI 1063605202
$3,614.33
in general payments reported to CMS, 2019-2025
34 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $839 · 2023: $940 · 2024: $801 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,576 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,575.71 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $525.65 | 2021-2024 | Myrbetriq, Xtandi |
| Boston Scientific Corporation | $303.06 | 2021-2024 | Rezum Generator |
| Antares Pharma, INC. | $283.91 | 2021-2025 | Xyosted |
| Urogen Pharma, INC. | $219.42 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.58 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $196.38 | 2023-2025 | Orgovyx |
| Axonics, INC. | $180.77 | 2021-2024 | Bulkamid |
| Janssen Biotech, INC. | $168.27 | 2024-2025 | Erleada |
| Myriad Genetic Laboratories, INC. | $155.82 | 2021-2023 | Prolaris |
| Pfizer INC. | $155.17 | 2023-2025 | |
| Progenics Pharmaceuticals, INC. | $147.57 | 2024 | |
| Abbvie INC. | $139.14 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $121.30 | 2024-2025 | Adstiladrin |
| Immunitybio, INC. | $120.00 | 2025 | |
| Clarus Therapeutics INC. | $74.97 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $74.45 | 2025 | Provenge |
| Coloplast Corp | $63.56 | 2023-2025 | Titan |
| Tolmar, INC. | $62.38 | 2024-2025 | Eligard, Jatenzo |
| Blue Earth Diagnostics | $55.28 | 2021 | |
| Allergan, INC. | $45.76 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $41.36 | 2023 | Bard Urinary Drainage Bag, Bardex I.C. Criticore Foley Tray Bardex Temperature-Sensing Foley Catheter |
| Photocure INC | $32.26 | 2023-2024 | Cysview |
| Novartis Pharmaceuticals Corporation | $28.91 | 2023 | |
| Merck Sharp & Dohme LLC | $28.23 | 2023 | Lynparza, Keytruda |
| Laborie Medical Technologies Corp. | $22.73 | 2025 | |
| Hollister Incorporated | $22.72 | 2023 | Infyna Chic |
| Pacira Pharmaceuticals Incorporated | $20.42 | 2023 | Exparel |
| Tolmar Pharmaceuticals, INC. | $20.01 | 2021 | |
| Olympus America INC. | $19.15 | 2024 | Itind System |
| Becton, Dickinson and Company | $17.22 | 2023 | Phasix Mesh |
| Azurity Pharmaceuticals, INC. | $15.64 | 2025 | Azmiro |
| Mission Pharmacal Company | $14.77 | 2021 | |
| Myovant Sciences INC. | $13.37 | 2021 | |
| Teleflex LLC | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Till listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.